Epilepsy Medication Denied by Insurance? Appeal Guide

Epilepsy affects roughly 3.4 million Americans, and nearly one in three patients develops drug-resistant epilepsy (DRE) — requiring newer antiepileptic drugs (AEDs) that insurers routinely deny. These denials can have life-threatening consequences: uncontrolled seizures elevate the risk of SUDEP (Sudden Unexpected Death in Epilepsy), driving restrictions, falls, and lost employment. Yet fewer than 1% of people who receive a denial letter ever appeal. Filing costs nothing, and appeals succeed at meaningful rates.

Why Insurers Deny Epilepsy Medications

Not medically necessary. The insurer's utilization reviewer determined the medication does not meet their internal clinical criteria — often using tools like Milliman or InterQual that are more restrictive than American Academy of Neurology (AAN) guidelines. These determinations frequently contradict the treating neurologist's clinical judgment.

Step therapy (fail-first) requirement. Insurers mandate that patients try older, cheaper AEDs before approving newer agents such as Vimpat, Briviact, Xcopri, or Epidiolex. The International League Against Epilepsy (ILAE) defines DRE as failure of two or more adequate AED trials. Once that threshold is met, further step therapy requirements are clinically unjustifiable and directly challengeable.

Prior Authorization Denied: How to Appeal" class="auto-link">Prior authorization not obtained or expired. Many newer AEDs — including Epidiolex, Vimpat (lacosamide), Briviact (brivaracetam), and Xcopri (cenobamate) — require prior authorization. Claims may be denied if authorization was never obtained, expired, or lapsed between approval and dispensing.

Experimental or investigational classification. Insurers occasionally label FDA-approved medications as experimental. Xcopri (cenobamate), FDA-approved in 2019, was shown in the REDUCE clinical trial to achieve a 21% seizure-free rate — unprecedented for an oral AED. Denying it as experimental is factually and legally indefensible.

Insufficient documentation. The claim lacks records explicitly demonstrating medical necessity under the insurer's criteria. Accurate ICD-10 coding under the G40.x category is critical: G40.019 (intractable localization-related epilepsy), G40.311 (Lennox-Gastaut syndrome), and G40.42 (Dravet syndrome) directly signal DRE severity to reviewers.

How to Appeal

Step 1: Decode the Denial Letter

Read the denial carefully and identify the exact reason code and policy provision cited. Request the insurer's clinical policy bulletin (CPB) used to evaluate your claim — you are legally entitled to this under ERISA 29 CFR § 2560.503-1 and ACA 45 CFR § 147.136. The CPB specifies the exact criteria you must satisfy.

Step 2: Document Prior AED Failures with Precision

Build a complete AED trial history: each drug name, dose, duration, and the specific reason discontinued. Frame this history explicitly against the ILAE 2010 definition of DRE. If the patient has failed two or more adequate AED trials, state this conclusion explicitly in the appeal — the insurer's step-therapy requirement has already been satisfied.

Step 3: Obtain a Targeted Neurologist Letter

Your neurologist's letter is the cornerstone of the appeal. It must include: your ICD-10 G40.x diagnosis code, the ILAE DRE classification, all prior AED trials with outcomes, the specific clinical rationale for the denied drug (mechanism of action, seizure type compatibility), relevant AAN Practice Guidelines citations, and an assessment of SUDEP risk from continued inadequate seizure control.

Step 4: Address the Denial Reason Point by Point

If denied for step therapy, document that prior failures satisfy ILAE DRE criteria and that requiring additional failures poses patient safety risks. If denied as experimental, cite FDA approval date, AAN guideline support, and published trial data (REDUCE trial for cenobamate, GWCARE1 for Epidiolex, PACE for VNS). If denied for lack of prior authorization, confirm whether emergency circumstances applied.

Step 5: Submit and Track

Send by certified mail and through the insurer's online portal. Keep delivery confirmations. Note the insurer's response deadline: 30 days for pre-service, 60 days for post-service under ACA; 72 hours for expedited urgent appeals under 45 CFR § 147.136.

Step 6: Escalate if Denied

Request External Independent Review: Complete Guide" class="auto-link">external review — an independent physician reviews your case at no cost to you. Request a peer-to-peer review between your neurologist and the insurer's medical director. File a complaint with your state department of insurance. For ERISA employer plans, consult an attorney about federal court review under ERISA § 502(a)(1)(B) after administrative exhaustion.

What to Include in Your Appeal

• Denial letter with specific reason code and policy provision cited
• Neurologist's letter citing ICD-10 G40.x code, ILAE DRE classification, and AAN guidelines
• Complete AED trial history: drug, dose, duration, and reason discontinued for each
• ILAE DRE documentation (failure of two or more adequate AED trials)
• Clinical trial data supporting the denied medication (e.g., REDUCE for cenobamate)
• SUDEP risk documentation if applicable — especially relevant for tonic-clonic seizures

Fight Back With ClaimBack

Epilepsy medication denials hinge on clinical documentation — whether your neurologist's records explicitly satisfy the insurer's AED step-therapy criteria and the AAN-based medical necessity standard. ClaimBack generates a professional appeal letter in 3 minutes, citing AAN guidelines, ICD-10 G40.x documentation requirements, and ILAE DRE criteria specific to your denial. Start your free claim analysis → Free analysis · No credit card required · Takes 3 minutes

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs External Insurance Appeal